RAB Symposium 2022
- The program of the 2022 International RAB symposium addressed the field of GPCR antibody research with specific highlights on:
- anti-GPCR antibodies as biomarker in disease and therapeutic response
- anti-GPCR antibody-mediated pathways
- regulation of anti-GPCR abs
- Identification of novel therapeutic targets
- Our aim is to bring scientists together, initiate discussions and stimulate research on these challenges. We would like to strengthen the research network to:
- identify new pathogenic targets, biomarkers and signalling pathways to find a holistic way to understand diseases
- To identify effectors that influence the disease-specific transcriptome and secretome
- understand how environmental factors and genes can be transformed into molecular pathways
- Develop novel therapeutic strategies
| 9:00 a.m. | Opening Gabriela Riemekasten, Yehuda Shoenfeld, Carmen Scheibenbogen |
| 09:10 -10:00 a.m. | Provocative statements Chairs: Carmen Scheibenbogen, Harald Heidecke All diseases are autoimmune diseases Yehuda Shoenfeld | Tel Aviv University Zabludowicz Center for Autoimmune Diseases, Tel Aviv, Israel All diseases are GPCR abs mediated diseases Gabriela Riemekasten | UKSH, Campus Lübeck, Lübeck, Germany |
| 10:15 a.m. | Session: COVID-19 and natural regulatory abs Chairs: Gabriela Riemekasten, Hanna Graßhoff Anti-GPCR abs in acute COVID-19 infection Otavio Cabral Marques COVID-Vaccination and anti-GPCR abs Tanja Lange Role of GPCR abs in Post-COVID syndrome Carmen Scheibenbogen PAR-1 abs in acute COVID-19 infection Reza Akbarzadeh |
| 13:00: 14:15 p.m. | Poster Talks, followed by discussion in the poster exhibition Chairs: Alexander Hackel, Antje Müller |
| 15:35 p.m. | Progress in preclinical models to measure RAB ab effects Chairs: Lars Klareskoog, Thomas P. Sakmar Animal models Xinhua Yu Modification of animal models and GPCR/monoclonal abs Frank Petersen Stroke and anti-GPCR abs Matthias Endres |
| 15:35 p.m. | Anti-GPCR binding biology Chairs: Frank Petersen, Xinhua Yu Multiplexed validation of anti-GPCR antibodies Thomas P. Sakmar Glycokalyx as novel player for anti-GPCR abs and for the modulation of receptor stimulation? Mai Jäpel Antibody-induced proteom Paulina Mackedanz |
| 17:00 p.m. | Closing |
| 09:00 a.m. | Natural RAB-induced signalling Chairs: Jürgen Bernhagen, Carmen Scheibenbogen Antibody cluster in vasculitis patients Carlotta Meyer Signalling of GPCR abs in different cellular models Rusan A. Catar Anti-GPCR-abs as Biomarker for PsA and Colitis Ulcerosa Hanna Graßhoff |
| 10:55 a.m. | Therapy Chairs: Camilla Svensson, Tanja Lange Aptamer BQ007, a novel therapeutic agent? Bettina Hohberger Interfering with atherogenic GPCR functions by peptides Jürgen Bernhagen |
| 13:00 p.m. | Fibromyalgia and ME/CSF as another challenge Chairs: Otavio Cabral-Marques, Carmen Scheibenbogen Fibromyalgia: ab-mediated pathogenesis Camilla I. Svensson Role of GPCR abs in chronic fatigue syndrome Franziska Sotzny Functional (catalytic) antibodies unravel autoimmune frequency in psychiatric disorders Kamalanathan AS Sivasankaran GPCR abs and confounding factors: Learning from fibromyalgia Tanja Lange |
| 15:05 p.m. | New pathogenesis insights from SSc Chairs: Reza Akbarzadeh, Yehuda Shoenfeld GPCR abs in systemic sclerosis Susanne Schinke CXCR3 abs and cardiovascular diseases Felix Müller Metabolom and anti-GPCR abs Sebastian Jendrek GPCR abs and EVs in SSc - the bad boys affecting immune cell function Alexander M. Hackel |
| 16:40p.m. | Lecture Chair: Gabriela Riemekasten EVs and antibody-interactions David S. Pisetsky |
| 17:10 p.m. | Closing Gabriela Riemekasten, Yehuda Shoenfeld, Carmen Scheibenbogen |